A detailed history of Baker Avenue Asset Management, LP transactions in Abb Vie Inc. stock. As of the latest transaction made, Baker Avenue Asset Management, LP holds 110,164 shares of ABBV stock, worth $18.2 Million. This represents 0.64% of its overall portfolio holdings.

Number of Shares
110,164
Previous 101,286 8.77%
Holding current value
$18.2 Million
Previous $17.4 Million 25.23%
% of portfolio
0.64%
Previous 0.49%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$163.84 - $199.33 $1.45 Million - $1.77 Million
8,878 Added 8.77%
110,164 $21.8 Million
Q2 2024

Aug 07, 2024

BUY
$154.79 - $180.76 $1.55 Million - $1.81 Million
10,021 Added 10.98%
101,286 $17.4 Million
Q1 2024

May 10, 2024

BUY
$159.82 - $182.1 $199,295 - $227,078
1,247 Added 1.39%
91,265 $16.6 Million
Q4 2023

Feb 13, 2024

BUY
$137.6 - $154.97 $975,721 - $1.1 Million
7,091 Added 8.55%
90,018 $14 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $349,471 - $404,564
2,616 Added 3.26%
82,927 $12.4 Million
Q2 2023

Aug 11, 2023

BUY
$132.51 - $164.9 $1.22 Million - $1.52 Million
9,242 Added 13.0%
80,311 $10.8 Million
Q1 2023

May 15, 2023

SELL
$144.61 - $166.54 $6.31 Million - $7.26 Million
-43,623 Reduced 38.03%
71,069 $11.3 Million
Q4 2022

Feb 13, 2023

SELL
$138.31 - $165.87 $699,710 - $839,136
-5,059 Reduced 4.22%
114,692 $18.5 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $1.2 Million - $1.38 Million
8,977 Added 8.1%
119,751 $16.1 Million
Q2 2022

Aug 03, 2022

SELL
$137.62 - $174.96 $13.8 Million - $17.6 Million
-100,612 Reduced 47.6%
110,774 $17 Million
Q1 2022

May 16, 2022

SELL
$131.98 - $163.75 $5.77 Million - $7.15 Million
-43,688 Reduced 17.13%
211,386 $34.3 Million
Q4 2021

Feb 11, 2022

BUY
$107.43 - $135.93 $2.48 Million - $3.14 Million
23,113 Added 9.96%
255,074 $34.5 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $869,394 - $986,893
8,171 Added 3.65%
231,961 $25 Million
Q2 2021

Aug 16, 2021

BUY
$105.21 - $117.21 $1.38 Million - $1.53 Million
13,073 Added 6.2%
223,790 $25.2 Million
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $467,613 - $514,786
4,571 Added 2.22%
210,717 $22.8 Million
Q4 2020

Feb 17, 2021

BUY
$80.49 - $108.67 $2.26 Million - $3.05 Million
28,059 Added 15.76%
206,146 $22.1 Million
Q3 2020

Nov 16, 2020

BUY
$85.91 - $100.83 $791,145 - $928,543
9,209 Added 5.45%
178,087 $15.6 Million
Q2 2020

Aug 12, 2020

BUY
$73.37 - $98.18 $6.89 Million - $9.22 Million
93,926 Added 125.31%
168,878 $16.6 Million
Q1 2020

May 14, 2020

SELL
$64.5 - $97.79 $1.93 Million - $2.93 Million
-29,974 Reduced 28.57%
74,952 $5.71 Million
Q4 2019

Feb 14, 2020

SELL
$72.13 - $90.25 $254,402 - $318,311
-3,527 Reduced 3.25%
104,926 $9.29 Million
Q3 2019

Nov 15, 2019

BUY
$62.98 - $75.72 $1.5 Million - $1.8 Million
23,739 Added 28.02%
108,453 $8.21 Million
Q2 2019

Aug 14, 2019

BUY
$65.7 - $83.98 $4.49 Million - $5.74 Million
68,298 Added 416.05%
84,714 $6.16 Million
Q1 2019

May 15, 2019

SELL
$77.14 - $90.79 $1.11 Million - $1.31 Million
-14,418 Reduced 46.76%
16,416 $1.32 Million
Q4 2018

Feb 14, 2019

BUY
$77.85 - $96.01 $163,407 - $201,524
2,099 Added 7.3%
30,834 $2.84 Million
Q3 2018

Nov 15, 2018

SELL
$88.91 - $98.84 $740,620 - $823,337
-8,330 Reduced 22.47%
28,735 $2.72 Million
Q2 2018

Aug 14, 2018

BUY
$89.78 - $106.23 $291,605 - $345,035
3,248 Added 9.6%
37,065 $3.43 Million
Q1 2018

May 15, 2018

BUY
$92.01 - $123.21 $611,038 - $818,237
6,641 Added 24.44%
33,817 $3.2 Million
Q4 2017

Feb 14, 2018

BUY
$89.56 - $98.21 $837,027 - $917,870
9,346 Added 52.42%
27,176 $2.63 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $127,266 - $162,558
1,822 Added 11.38%
17,830 $1.58 Million
Q2 2017

Aug 11, 2017

BUY
N/A
16,008
16,008 $1.16 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $292B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Baker Avenue Asset Management, LP Portfolio

Follow Baker Avenue Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Avenue Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Avenue Asset Management, LP with notifications on news.